GlassScriptPhysician profile
Equbal Kalani
NPI 1013900588
$7,951.72
in general payments reported to CMS, 2019-2025
20 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $556 · 2021: $577 · 2022: $525 · 2023: $866 · 2024: $958 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898 · Travel and Lodging: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.71 |
| Travel and Lodging | $1,266.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,929.15 | 2019-2025 | Mitraclip, Aveir, Navitor |
| Boston Scientific Corporation | $1,079.25 | 2019-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Mylux Patient Kit With Mobile Device |
| Medtronic, INC. | $609.04 | 2021-2025 | Micra, Reveal Linq |
| Novo Nordisk INC | $512.35 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.20 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $337.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $281.38 | 2022-2025 | |
| Pfizer INC. | $197.04 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.99 | 2019-2025 | Lifevest |
| Silk Road Medical, INC. | $113.60 | 2020-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Lilly USA, LLC | $57.21 | 2023-2024 | Mounjaro |
| Biotronik INC. | $52.27 | 2025 | Renamic Neo, Biomonitor |
| Astrazeneca Pharmaceuticals LP | $34.05 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.40 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $31.42 | 2023-2024 | Inpefa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.35 | 2021 | |
| Scpharmaceuticals INC. | $21.36 | 2024 | |
| Amgen INC. | $18.66 | 2021 | |
| Elutia, INC. | $13.45 | 2023 | |
| Merck Sharp & Dohme LLC | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Equbal Kalani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.